Get started

Smallcaps

RTY1!, All Eyes on Small CapsHere is a dissected daily chart of Russell 2000 futures with important levels to watch. As of today, the index remains the weakest among the others. Last week it tested an important trend line but managed to close above it. The index has an interesting behavior that could be used to trader's advantage. For example, it may be in a catch up mode and trend well while the rest of the indices are aimlessly chopping or it may show a hint where the rest of the indices will be heading. Say, as an investor where do I put my money to work if I can see the Nasdaq and S&P 500 are at all time highs? The Russell is far from the all time highs and has plenty of upside potential. I drew a few projected areas above and beyond the current action. In case the prices break above that would be a nice upside trend to fill the projected area. In case of a breakdown of the trend line the price can fill the existing area and still find enough buyers to remain inside. Let's watch the price development next week. Being close to the upper edge of the existing balance the upside potential is there. The only warning sign is a notable negative divergence. 04/21/2019
CME_MINI:RTY1!
by SviCapital
5
Long NCTY entered into JV at discounted price premarket up 60%NASDAQ:NCTY NASDAQ:TSLA The Chinese internet company The9 Limited (Ticker NCTY) (“The9”) made an announcement yesterday on its signing of a joint venture agreement with Faraday Future (“FF”), betting on the USD200 billion EV market. According to PR Newswire, The9 will be a 50% partner in the joint venture with control over business operations. FF will contribute the use right in a piece of land in China for electric cars manufacturing and will grant the joint venture an exclusive license to manufacture, market, distribute and sell FF’s new brand V9 model and other potential selected car models in China, with The9 providing financing up to US$600 million to the JV. The JV will manufacture, market and distribute the sales of V9 model, a flagship luxury EV based on the technology and design concepts of the FF 91. The9 was one of the earliest Chinese internet company who got listed on the US stock market since 2004 and despite its recent lackluster share price performance, it appears to remain as a stock that is actively followed by the investor community. During the past few years, the company has demonstrated persistent endeavor venturing into other technology related spaces outside of online games. And this JV with FF sounds like just the right project for the company to excel again. FF is a California based EV manufacturer and has allegedly recruited talent from Apple, Tesla SpaceX and other well-known automakers. It has nearly 400 patents and more than 2,000 pending. The all-electric and autonomous-ready FF91 model which the V9 is based on, is the first production vehicle and flagship model of FF. FF’s website highlighted the performance of FF91 - 3 electric motors, 0-60 MPH in 2.39 seconds and 1,050 horsepower. The pre-production of FF91 was finished in August 2018. FF’s latest round of funding came from a Hong Kong listed company Evergrande Health (“EH”). According to the announcement on the HK exchange made by EH back in June 2018, EH acquired 45% equity interest in FF for US$2B, thereby giving FF an implied valuation of US$4.4B. During the two-month period after its announcement of investing into FF, the stock price of EH went up by 278% from HKD4.6 to its peak price at HKD17.4, representing an increase in market cap of EH by a staggering amount of US$14B! What is more interesting is that, while this JV is expected to account for most of FF’s value, the pre-money valuation that The9 is paying for this JV is only USD600M, representing a steep discount to FF’s previous round valuation. So, what is the catch? It appears that Jia Yueting, the ultimate shareholder of FF, has not returned to China since the LeTV incident in 2017 and this has made life difficult for FF to set foot in China. Now with The9 controlling the business operation of the JV, it is expected that The9 will take lead on the JV’s business development in China. Current CEO and major shareholder of The9, Zhu Jun (“Zhu”) ranks among the first generation of Chinese Internet tycoons. Zhu is well respected within the business community and maintains good relationships with the government, especially those in the Yangtze River Delta where the JV operates. As to how this deal would affect The9’s share price – what we know is that FF’s last round valuation paid by EH was USD4.4B and the share price of EH suggested that FF’s valuation should be even higher. Whilst at this moment we might not have as much information as we would like to deduce an exact valuation of the JV based on FF’s valuation, I incline to think that the 50% JV stake that The9 holds will likely be worth north of USD1B. This will translate into an increase of The9’s share price by at least USD24.0 per share. However, it would make more sense to look at the market implied valuation of FF of around USD8.9B based on a one-month average share price of EH since its investment into FF. This market approach give rise to a JV’s valuation of USD4.4B on a pre-money basis and USD5.0B on a post-money basis. Accordingly, The9’s 50% stake of the JV should worth USD2.5B on a post-money basis and therefore USD1.9B on a pre-money basis. This will translate into an astonishing USD46.1 additional equity value per share
NASDAQ:NCTYLong
by smallcappppppp
$RUT $SPY Small Caps? - Loosing Steam or Taking a Breather?Small cap equities have had a fantastic run since the beginning of 2019, so much so that the asset class is up 12.72% year-to-date. However, the asset class has been loosing a little bit of luster as of late, especially in relation to their large cap counterparts. Since mid-February 2019, the price ratio between small cap and large cap equities (RUT/SPY as a proxy) hit its 200-day moving average and failed to breakthrough, and in turn, has been falling since. In addition, its Smart Money Indicator reading shows it is 1.84, well of its highs of 1.98 as seen earlier in the year, indicating that this trend has some legs to stand on. Thus, this lends credence to the fact that global investors have been rotating out of small cap stocks and into large cap stocks. We believe that this trend is due to two reasons: 1) Improving Trade Deal Prospects Between the US and China - As talks of a trade deal continue to progress well between the two nations, investors have begun to move money back into large cap sectors and names that will greatly benefit from the reduction, or even removal, of trade barriers between the US and China. This can been in the fact that trade sensitive sectors such as technology (up 16.67%) and industrials (14.44%) have been some of the top performing sectors year to date. 2) Slowing Global Economy - With the current economic expansion growing tired and weary, from a factor perspective, investors have been moving money out of riskier segments of the equity market and into “safer” areas such as large cap stocks, companies with stable earnings growth, value stocks, and firms with lower betas in relation to the general market. Investors have realized, and rightfully so, that though this recent run in the markets has been solid, the macroeconomic backdrop continues to be an area of concern. Overall, though we think that small caps still have some to run, investors should take heed over the fact that money is moving out of this segment of the equity market and into large cap equities. Furthermore investors should be cautious if this trend continues.
TVC:RUT
by EconomicsGlobal
$SELB Beats Earnings by .10/Phase 2 Results/Cash into 2020Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19, interim six-month data expected in 4Q19 Collaboration with CureCN projected to dose first patient with combination of ImmTOR + AAV gene therapy candidate in 2H19 Company raises $33M in gross offering proceeds and $31.3M in net proceeds in 1Q19, cash runway into 1Q20 “During 2018 we laid a strong groundwork for a year of execution in 2019. We kicked off the year by streamlining the company through a corporate restructuring, which is projected to cut our cash burn rate by 19%. We then completed an equity fundraise of approximately $33 million in gross proceeds and $31.3 million in net proceeds, and anticipate reporting key milestones for both our chronic refractory gout and gene therapy programs. We continue to believe that our lead program, SEL-212, has the potential to address several unmet needs in chronic refractory gout patients, including sustained serum uric acid reduction, reduced painful flares and once monthly dosing, and we look forward to initiating the planned six-month head-to-head (COMPARE) clinical trial against Krystexxa this month,” said Carsten Brunn, Ph.D., President and CEO of Selecta. “We also look forward to further advancing our ImmTOR + AAV gene therapy combination product candidate in Crigler-Najjar Syndrome in collaboration with CureCN in the second half of the year and identifying other ways to advance our ImmTOR platform and grow our strategic partnerships.” Effective December 1, 2018, Carsten Brunn, Ph.D., assumed the role of President and CEO of Selecta, following his previous position as President of Pharmaceuticals for the Americas Region and member of the Global Pharmaceutical Executive Committee at Bayer. Reported Phase 2 Data: Selecta has reported data from its Phase 2 trial showing that 66% of evaluable patients (21/32), maintained serum uric acid (sUA) levels of <6mg/dL after five oncemonthly treatments of SEL-212 at doses of 0.1 or 0.15 mg/kg of ImmTOR in combination with 0.2mg/kg of pegadricase. Furthermore, reduced total urate burden and lowered flare rates and severity were observed in the Phase 2 clinical trial, and SEL-212 continued to be generally well tolerated. Collaboration with CureCN Consortium Projected to Dose First Patient in 2H19: In September 2018, Selecta announced a collaboration with CureCN, a European consortium, for an ImmTOR+AAV gene therapy combination product candidate in Crigler-Najjar Syndrome, building upon preclinical work that was published together with Genethon in Nature Communications in October 2018. Selecta expects CureCN to initiate preclinical toxicology studies in the first half of 2019 and for the combination product candidate to enter the clinic in the second half of 2019. Selecta expects to initiate a Phase 2 head-to-head (COMPARE) clinical trial of SEL-212, compared to the current FDA-approved uricase therapy, Krystexxa, in the first quarter of 2019. An interim six-month data readout is projected for the fourth quarter of 2019, with a full statistical data analysis expected in the first quarter of 2020. The results of the COMPARE trial are expected to inform the design of the planned Phase 3 clinical trial of SEL-212, which the company plans to initiate in the fourth quarter of 2019. Cash Position: Selecta had $37.7 million in cash, cash equivalents and restricted cash as of December 31, 2018, which compares to cash, cash equivalents and short-term investments of $50.5 million at September 30, 2018. The company currently has a cash runway into the first quarter of 2020, which includes proceeds net of underwriting discounts and commissions of $31.3 million from the company’s recent follow-on offering in January 2019. Corporate Restructuring Completed in January 2019: Selecta completed a corporate restructuring that reduced the company’s workforce by 36 percent as of January 3, 2019. This reduction, coupled with a reprioritization of the company’s pipeline programs, is projected to reduce the yearly cash burn by 19 percent. Successfully Completed a $33.3 Million Public Offering; Providing Cash Runway into 1Q20: In January 2019, Selecta completed an underwritten public offering of 22,188,706 shares of its common stock, at a price to public of $1.50 per share, resulting in net proceeds to Selecta of $31.3 million, after deducting underwriting discounts and commissions.
SLong
by StockGuild
+60% in 30 days "Pennystock" Bounce Strategy. +30% bounce comingThis is another trade that I really like to do, even though this stock is not under a penny, I use this strategy most for small caps and penny stocks where volume plays an incisive role and provides great and clear signals. Once again, our tool of choice is the Spectro M2 And we are using only two features with this robust trading plan. 1 - Volume Analyzer The setting used is the Sine Wave Method( Spectro M2 offers 4), and it is the green/orange/red background we can see under the price action. It tells you the direction and strength of the move based on the volume. 2 - Adaptative Fibonacci It's an extremely powerful tool that Spectro M2 offers, that provides you instantly all the levels you should be watching for your entry/exit points. 3 - Buy Zone This one I made with a simple visual average of the lowest low in this channel and the lowest closes, it doesn't have to be super precise, as long as you know the lowest low for your stop-loss any buy-limit order in this area is fine. It's a long trade but it didn't happen yet so wait for the conditions to confirm otherwise you're not following the strategy. Consider breaking your buy-limit order all across the buy-zone to get a good avg entry price.
HLong
by spectertrading
Small Cap Stock to Watch: NSTG with Dark Pools, Pro TradersNSTG had a speculative momentum run out of a short term bottom. This small-cap stock has finally broken out of its long term trading range to a new high. Now it needs to shift sideways to avert a falling stock price. There is some mild accumulation in the consolidation patterns that are representative of one or two Dark Pool giants and some pro traders who both stabilize and control price to a neat and tidy-looking consolidation. NSTG is not a buy at the moment as the run is overextended at this point, but it is worth considering for a possible watchlist candidate since it is in Nano technology, which is finally forging ahead again with more products moving to the market acceptance phase.
NEducation
by MarthaStokesCMT-TechniTrader
Triad- 10% jump on Friday with plenty more to come.Triad is inside and up on monthly and weekly timeframes, and in full timeframe continuity to the upside. This company has excellent fundamentals including a large amount of cash equal to over 30% of its current valuation. Currently hugely undervalued due to some legal complications- a former board member taking the company to court- however with the high court ruling in the company's favour and a 10% jump in price on friday after a multi month period of consolidation, there is a good chance a more realistic price will now be found.
LSE:TRDLong
by chrisatom
$LRSV To Go Current. Now Fully Integrated in the Pet CBD MarketThe company has stated that they will be fully current within the next 10 business days. The company has been posting CBD and marijuana oriented tweets and with their brand new website stating; “LinkResPet, a subsidiary of Link Reservations Inc, Produces a line of CBD products specifically tailored for cats, dogs and horses.” The website can be viewed here: www.linkrespet.com . The chart shows that the William volume accumulation indicator points bullish, volume price trend points bullish and the MACD is also bullish making this a great chart play and potential RM play in our opinion.
OTC:LRSVLong
by StockGuild
All the way to Resistance? & Inarguable FundamentalsGuess myself and a very few group of others had underestimated the amount of faith in this market. I had wholeheartedly felt we would see the Dow cut short of the move towards the resistance line set by the other 3 peaks preceding. Though I had left room to suggest the possibility of this happening, I did have doubts and I did voice those doubts with others, so I was wrong, and I owe gratitude to my counter parts for being fair enough with me to reasonably say, “well, maybe”. That said, the long term perspective still reads the same. The fundamentals are still shallowing up, and the technicals, when compared to previous end-cycles have very distinctly similar patterns, if we are to truly push back from this point of resistance and engage in a massive sell off shortly after. This time, I’d like to be a little more open and take a position that we will test the resistance line at least once more on the way day. And this is not for the sake of holding weight to the recent news on positive earnings, as anyone that truly invests knows that these earnings were only “solid” because they came close to juncture with the wall st estimates. If we remember, however, those earnings estimates were revised downward from previous quarters, so it means nothing that we met the expectations of a market still slowing down fundamentally. A greater crisis that I think is looming still goes back not large-cap corporate debt but the debt on personal financing, consumers and credit cards. Those are all at records. Coupling that with the Fed Reserve’s charts depicting the total money supply in “deposit accounts”, we see that those accounts are dwindling pretty hard. This loss of deposit away from the market correlated fairly when when regressed to debt repayment expectations. So, liquidity leaving the market is always negative news for future earnings. That said, one other concern I have is with the small-cap companies. Very poor earnings growth for just under half of them, and they are more leveraged in this hour than in any point in time in the index history. I can foresee a lot of negativity in the Russell 2000. Lower earnings make it harder to find coverage on interest payments, and should anyone need to survive by refinancing, they will be doing so at markedly higher interest rates when compared to 2013-2016.
DJ:DJIShort
by thehoplite
Expecting RUT to find support around 1225I believe there will some additional selling before we can see the Rusell find some support around 1220 - 1230 which matches with a 38% retracement from the highs we saw just a couple of months ago, additionally that area matches with the uptrend that started at the end of the financial crisis in Feb 2009. If that long term trend breaks I think we could see it go down all the way to the 2016 lows before it starts moving up again. We might be seeing a bunch of sideways and down movement as we head towards 2019. Happy Holidays :D
TVC:RUT
by the_no_factor
$SL1 down trend breakSL1 has remained in down trend since the 4.2c high in July but is now showing signs of a return to strength. Mid September volume reached an all time low around the base established at 1.8c, since this low the volume has stepped back in lifting the SP to the first resistance point at around 2.5c where significant volume has remained. The next resistance point in this case becomes the target at 3.5c This target is supported by underlying fundamental changes in the company which has recently transitioned to a miner with targeted first shipment of zinc early in the October quarter. The second catalyst in support of growth is the highlighted tenement acquisition by the end of December this year. My initial target is 3.5c which represents a 52% increase from the last traded price, stops set at 1.8c which is the all time low representing a favorable risk to reward ratio of 2.4
SLong
by Michaeljob
EKSO - Buy and hold for future exoskeleton growthI have been wanting to get long-term invested in the stocks that I think will greatly benefit from future technology trends. I believe that pure robotics are further in the future than most people realize, but wearable robotics are much closer to adoption. With that opinion I want to be positioning myself in the exoskeleton market. There are a number of very small exoskeleton companies but the one that stands out me the most is EKSO. A few things that stand out are that they are not only penetrating the medical market but they are also heavily focused on the industrial market, where as the other exoskeleton companies are primarily focused on the medical market. Ekso has also recently landed a few contracts, one with the VA and another with Ford that will help them generate the revenue they need to become profitable. As with most small growth companies the biggest risk here is that they are not yet profitable and will need to generate cash flow through debt or stock dilution, which makes it very important to not jump in too earlier. Up until now it has been too early to buy and hold but I believe with the Ford and VA contracts they may be a few quarters from turning the corner and becoming profitable. Price is still a little rich at this point but I will be looking to buy a little bit around $2.20 - $2.00 as a long term speculative buy-and-hold.
NASDAQ:EKSOLong
by krugman87